Alphamab Oncology: Trading Debut, Valuation Scenario Analysis
Alphamab Co Ltd (9966 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
490 Views
Alphamab Oncology IPO: Valuation Easy to Swallow
Alphamab Co Ltd (9966 HK) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
521 Views
Alphamab Oncology IPO Initiation: Clear Diagnosis
Alphamab Co Ltd (1728643D CH) is a pre-revenue biotech company with a focus on research and development, manufacturing and commercialisation of...
473 Views
SinoMab (中国抗体) IPO - A Hard Sell
SinoMab is a Hong Kong-based biotech company with a focus on mAb-based biologics for the treatment of immunological diseases, launched its book...
526 Views
Innovent Biologics - Promising Phase I Results for Lung Cancer
In the recent 2019 World Conference on Lung Cancer held in Spain, Innovent Biologics reported preliminary results from a Phase I clinical trial on...
425 Views